ACSL1: A Potential Drug Target and Biomarker (G2180)

Target Name: ACSL1

NCBI ID: G2180

ACSL1

ACSL1: A Potential Drug Target and Biomarker

ACSL1 (acyl-CoA synthetase 1) is a gene that codes for a protein known as acyl-CoA synthetase 1. This protein is a key enzyme in the citric acid cycle, which is a central metabolic pathway that occurs in all eukaryotic cells. The citric acid cycle is responsible for the production of energy from the food we consume and is a crucial step in the production of ATP, the energy currency of the cell.

Overview of ACSL1

The acyl-CoA synthetase 1 protein is expressed in most eukaryotic cells and is involved in the citric acid cycle. It is a 28kDa protein that consists of 215 amino acids. ACSL1 is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the cytoplasm of the cell.

The function of ACSL1 is to catalyze the conversion of acetyl-CoA to acyl-CoA in the citric acid cycle. This conversion is critical for the production of ATP from the food we consume. During the citric acid cycle, acetyl-CoA is converted to acyl-CoA through the intervention of ACSL1. The acyl-CoA synthetase 1 is also involved in the production of other molecules, including malate and succinate, which are involved in the citric acid cycle.

Drug Targeting ACSL1

Due to its involvement in the citric acid cycle, ACSL1 has been identified as a potential drug target. Several studies have suggested that inhibiting ACSL1 may be a useful way to treat various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the reasons why ACSL1 has been identified as a potential drug target is its involvement in the production of ATP, which is a crucial energy source for the cell. In neurodegenerative diseases, the production of ATP is often impaired, which can lead to the progression of the disease. Therefore, inhibiting ACSL1 has been suggested as a potential therapy for neurodegenerative diseases.

Another potential mechanism by which ACSL1 may be targeted is its role in the production of malate and succinate, which are involved in the citric acid cycle. Malate and succinate have been shown to have various functions in the cell, including the production of energy, the maintenance of cellular homeostasis, and the regulation of inflammation. Therefore, inhibiting ACSL1 may be a potential therapy for diseases that are characterized by the production of malate and succinate, such as cancer.

Biomarker

In addition to its potential as a drug target, ACSL1 has also been identified as a potential biomarker for several diseases. The production of ACSL1 is often affected by various factors, including nutrient availability, such as nitrogen and carbon availability, and can be used as a biomarker to track changes in cellular metabolism.

For example, ACSL1 has been shown to be involved in the production of succinate, which is a key intermediate step in the citric acid cycle. Therefore, the production of succinate has been used as a biomarker to track changes in cellular metabolism. Studies have shown that succinate levels are often reduced in diseases, such as cancer and neurodegenerative diseases, due to changes in cellular metabolism. Therefore, measuring succinate levels may be a useful way to track changes in cellular metabolism and may have implications for the diagnosis and treatment of these diseases.

Conclusion

In conclusion, ACSL1 is a protein that is involved in the citric acid cycle and has been identified as a potential drug target due to its involvement in the production of ATP and its role in the production of malate and succinate. In addition, ACSL1 has also been identified as a potential biomarker for diseases characterized by changes in cellular

Protein Name: Acyl-CoA Synthetase Long Chain Family Member 1

Functions: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:24269233, PubMed:22633490, PubMed:21242590). Preferentially uses palmitoleate, oleate and linoleate (PubMed:24269233). Preferentially activates arachidonate than epoxyeicosatrienoic acids (EETs) or hydroxyeicosatrienoic acids (HETEs) (By similarity)

The "ACSL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACSL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets